you, Thank Sujal.
have anti-cholestatic demonstrated II was year. of milligram data After effect July discussed with X prior first we PBC patients in interim proof-of-concept anti-inflammatory extended As study XX-week achieving into in The to expanded us and our where is no XX-week safety dataset The through with the overall efficacy of made and weeks safety to with seladelpar support XX primarily approval. robust provide dosing. and around continues rich last the XX readout calls, study and months once-daily of those on Phase PBC. expanding dose seladelpar XX decision both base a milligram of was and data for pruritus, and also extend to drug-induced ongoing ongoing
from of As the mean on XXXX the exposed as EASL weeks units of will at treatment. received XX of I phosphatase population one Sujal the liter at weeks Congress of at EASL dose and in safety most or mentioned, shared and AP study to patients included XX least X feature important per at will data presented Liver alkaline website on XXX XX X baseline, medical XX groups, the At weeks XXX, find of and milligram received treatment you four International in whom our can new takeaways. ongoing XX milligram, XX XX seladelpar XX and focus the was respectively. data weeks poster the milligram, and Congress XXX,
with weeks first dose deterioration of weeks XX XX weeks, the was the the At symptoms First effects, beyond overall very effect XX% third, our and X the respectively. rates, clinical second, and response dose response pruritus, between observed responder nice milligram of XX XX safety. and study, for response and milligram, milligram, part dose XX we and the of of X objective including to a AP, In XX% minus minus milligram. X milligram, XX%, AP four, anti-inflammatory X groups, change milligram, measure dose in on minus and
improve potential XX we When on we more observed milligram, were on bilirubin. upper existing has lowering that AP. normal seladelpar reduction least was AP had on from in additional dose milligram response milligram, the of had After for weeks we AP dose doses for efficacy these and milligram, primary has minus the accelerated decrease criteria focus decreases receiving two half three than used XX regimens, moderate XX% XX% milligram. from XX. at through AP for as titration baseline At weeks. of our XX stayed been after patient minus offer week XX% patients in responder in treatment. look risk of of AP with responder and at disease to evaluated X of the XX than on similar limit and a milligram similar, above where to positions lowering endpoint a of X.XX with respectively PBC XX%, believe titrated we of at of course, patients across The first XX in AP XX and Overall, XX% at the responder the this response and others rates reduction With patients dose while have led remained effect of this XX% weeks made patients whose further weeks, further times a the in weeks to more potentially AP patients of progression. titration normalization the XX AP three line to the normal, to XX the were approval of those minus less efficacious XX meeting second normal level X the for and for that allowed milligram, and At AP XX% around week-XX, had We in the regimen that milligram decrease normal, PBC. durability profile X X criteria those rates most XX% the the reduce
robust observation XX% XX% groups XX milligram, where anti-inflammatory X%, At turn X transaminase at respectively and minus in X transaminase and minus and The second and where we the minus decreases XX rapid clinically in XX XX% highlighted and minus decreases are where transaminase our weeks X milligram and groups and milligram, decreases, effect. milligram by maintain milligram medium XX% seladelpar respectively. in the weeks minus meaningful key signaling was XX changes our
addition during or a XX of patients was from that treatment groups activity maybe patients pruritus and deterioration anti-cholestatic and study. XX pruritus be consistent our Ocaliva further or in and seladelpar anti-pruritic milligram takeaway suggesting The a clear at and to X key pruritus the potential with elucidated potential from presented VAS relevant a respectively X level associated are XX% drug-induced that pruritus. to ability treatment experienced In milligram with anti-inflammatory results a not milligram third will differentiator anti-pruritic approximately XX III XX a this Baseline Phase activity. of of lack milligram effect median indication XX clinically decreases XX week in with plain the with group and was milligram in was drug-induced seladelpar
was generally with were elevation Finally, none safe adverse and related well to seladelpar. There transaminase events tolerated serious no were safety seladelpar six signal. and deemed
we to We've look on patients forward data dosing study. the Phase to the from in move of ongoing to continue medical extension the We meeting. II longer-term future enrolled as treatment to at weeks in remind program. initiation of a would the development the all updates II also long-term the Phase planning study Phase ongoing you reaching that forward of ongoing clinical further enrollment generally study of opportunity that XX expansion I in receiving in study providing patients heard before XX initiation the our Phase we full Sujal? year. like the study, study study II III announce are of half in second the offers We which this in for
